This federal contract award is for the delivery of PYLARIFY 100 DOSES, a radiopharmaceutical product used for positron emission tomography (PET) imaging of prostate cancer. The contract, valued at $360,872.00, was awarded to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc.
The contract is a delivery order under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has a firm fixed price pricing type. The awarding agency is the Veterans Integrated Service Network 10 (VISN 10), a component of the Department of Veterans Affairs (VA). The contract has an ultimate completion date of January 15, 2026 and was awarded on January 16, 2025. This award is not designated as a small business set-aside.
Lantheus Holdings, Inc., the parent company of the prime contractor, is an active federal contractor providing a range of radiopharmaceuticals, nuclear medicine supplies, and diagnostic imaging agents to government healthcare providers, including the VA and Defense Health Agency. The company maintains several significant Indefinite Delivery Vehicles (IDVs), such as Blanket Purchase Agreements, to facilitate the efficient procurement of these critical medical products.
Generated 1/15/25, 9:32 AM